Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are currently being treated with one of the following medications: abiraterone, apalutamide, darolutamide, or enzalutamide, taken at the doses specified in the official medication guidelines, and whose body levels of the medication have reached a stable, consistent level.
- People who are 18 years of age or older.
- People who have agreed to take part by signing a consent form.
Who may not be able to join:
- People who have conditions that might make it difficult for them to follow the steps and procedures required by the study.
- People who decline to sign the consent form agreeing to take part.
- People who have any condition that the doctor running the trial believes could get in the way of safe and appropriate participation in the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: + 39 0434 659667
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the reliability of innovative analytical methods based on DBS sampling for the quantification of abiraterone, apalutamide, darolutamide, and enzalutamide
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.